Eurolife snaps up Baxter’s form-fill-seal unit in India for undisclosed price

Eurolife Healthcare, a specialty drugmaker based in India, picked up the form-fill-seal infusion products unit of U.S.-based Baxter International for an undisclosed price.

The deal consolidates Eurolife’s position as a major player in the form-fill-sealed segment, BW Businessworld reported. The technology is used in sterile manufacturing of liquid drugs and intravenous fluids.

Under the terms of the acquisition, Eurolife gets the products and technology as well as Baxter’s facilities in India. 

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

It’s expected the sale will be closed by the end of the year.

“Eurolife is totally committed to making significant investments in the acquired facilities, in order to expand capacity to feed our flourishing FFS infusions business both locally and globally,” Sandeep Toshniwal, Eurolife’s CEO, said in a statement.

Eurolife, based in Mumbai, was founded in 2001. With the Baxter agreement under its belt it will have manufacturing facilities in Maharashtra, Tamil Nadu and Uttarakhand. The company currently markets to 22 countries in Asia, the Pacific region and Latin America.

Suggested Articles

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.

Pfizer is pushing back on a Thursday report claiming it suddenly revised its COVID-19 vaccine targets for 2020, saying it announced that last month.